Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| OGN | Organon & Co. | 2025-10-16 18:40:27 | 9.3 | -0.08 | -0.85 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OGN | 0001821825 | Organon & Co. | US68622V1061 | — | 464838035 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 30 HUDSON STREET | JERSEY CITY | NJ | 07302 | UNITED STATES | US | 551-430-6000 | 30 HUDSON STREET, JERSEY CITY, NJ, 07302 | 30 HUDSON STREET, JERSEY CITY, NJ, 07302 | — | Pharmaceuticals | 1923 | Kevin Ali | 10,000 | http://organon.com | 5,300,000,000 | 259,965,000 | 259,965,579 | Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. | 2025-10-10 20:33:50 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 5,300,000,000 | 0 | 0 | 257,950,149 | 2,311,893 | 0.9044 |
| 2023 | 5,300,000,000 | -3,300,000,000 | -38.3721 | 255,638,256 | 1,255,524 | 0.4936 |
| 2022 | 8,600,000,000 | 930,000,000 | 12.1252 | 254,382,732 | 745,553 | 0.2939 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Juan Camilo Arjona Ferreira | Chief Medical Officer, EVP | 2024 | 650,000 | 0 | 1,665,534 | 696,800 | 87,419 | 3,599,751 |
| Susanne Fiedler | Chief Commercial Officer, EVP | 2024 | 738,340 | 0 | 1,832,094 | 791,500 | 47,596 | 4,197,282 |
| Kevin Ali | Chief Executive Officer | 2024 | 1,250,000 | 0 | 9,160,555 | 2,512,500 | 1,444,372 | 17,117,424 |
| Matthew Walsh | Chief Financial Officer, EVP | 2024 | 900,000 | 0 | 2,831,423 | 964,800 | 200,700 | 5,746,922 |
| Joseph Morrissey | EVP | 2024 | 750,000 | 0 | 1,832,094 | 804,000 | 193,848 | 4,129,939 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 10,000 |
| 2023 | 10,000 |
| 2022 | 10,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 6,403,000,000 | 6,263,000,000 | 6,174,000,000 |
| Cost Of Revenue | 2,688,000,000 | 2,515,000,000 | 2,294,000,000 |
| Gross Profit | 3,715,000,000 | — | — |
| Research And Development Expenses | 469,000,000 | 528,000,000 | 471,000,000 |
| General And Administrative Expenses | 1,760,000,000 | 1,893,000,000 | 1,704,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | — | — | — |
| Net Income | 864,000,000 | 1,023,000,000 | 917,000,000 |
| Earnings Per Share Basic | 3.36 | 4.01 | 3.61 |
| Earnings Per Share Diluted | 3.33 | 3.99 | 3.59 |
| Weighted Average Shares Outstanding Basic | 257,046,000 | 255,239,000 | 254,082,000 |
| Weighted Average Shares Outstanding Diluted | 259,152,000 | 256,270,000 | 255,169,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 675,000,000 | 693,000,000 | 706,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,358,000,000 | 1,744,000,000 | 1,475,000,000 |
| Inventories | 1,321,000,000 | 1,315,000,000 | 1,003,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 994,000,000 | 756,000,000 | 747,000,000 |
| Total Assets Current | 4,348,000,000 | 4,508,000,000 | 3,931,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 1,168,000,000 | 1,183,000,000 | 1,018,000,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 8,753,000,000 | 7,550,000,000 | 7,024,000,000 |
| Total Assets | 13,101,000,000 | 12,058,000,000 | 10,955,000,000 |
| Accounts Payable | 1,153,000,000 | 1,314,000,000 | 1,132,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 20,000,000 | 9,000,000 | 8,000,000 |
| Other Liabilities Current | 134,000,000 | 206,000,000 | 184,000,000 |
| Total Liabilities Current | 2,718,000,000 | 2,918,000,000 | 2,512,000,000 |
| Long Term Debt | 8,880,000,000 | 8,760,000,000 | 8,913,000,000 |
| Other Liabilities Non Current | 977,000,000 | 412,000,000 | 411,000,000 |
| Total Liabilities Non Current | 9,911,000,000 | 9,210,000,000 | — |
| Total Liabilities | 12,629,000,000 | 12,128,000,000 | — |
| Common Stock | 3,000,000 | 3,000,000 | 3,000,000 |
| Retained Earnings | 1,010,000,000 | 443,000,000 | -331,000,000 |
| Accumulated Other Comprehensive Income | -649,000,000 | -541,000,000 | -564,000,000 |
| Total Shareholders Equity | 472,000,000 | -70,000,000 | -892,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 145,000,000 | 116,000,000 | 116,000,000 |
| Share Based Compensation Expense | 105,000,000 | 101,000,000 | 75,000,000 |
| Other Non Cash Income Expense | -41,000,000 | -31,000,000 | -26,000,000 |
| Change In Accounts Receivable | -383,000,000 | 212,000,000 | 123,000,000 |
| Change In Inventories | 131,000,000 | 230,000,000 | 220,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -157,000,000 | 163,000,000 | -237,000,000 |
| Change In Other Liabilities | -29,000,000 | -16,000,000 | 8,000,000 |
| Cash From Operating Activities | 939,000,000 | 799,000,000 | 858,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 175,000,000 | 251,000,000 | 196,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -513,000,000 | -260,000,000 | 0 |
| Tax Withholding For Share Based Compensation | 22,000,000 | 17,000,000 | 11,000,000 |
| Payments Of Dividends | 297,000,000 | 295,000,000 | 290,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 1,186,000,000 | 80,000,000 | 0 |
| Repayment Of Long Term Debt | 1,197,000,000 | 338,000,000 | 108,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -368,000,000 | -569,000,000 | -433,000,000 |
| Change In Cash | -18,000,000 | -13,000,000 | -31,000,000 |
| Cash At End Of Period | 675,000,000 | 693,000,000 | 706,000,000 |
| Income Taxes Paid | 293,000,000 | 135,000,000 | 214,000,000 |
| Interest Paid | 520,000,000 | 527,000,000 | 422,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 3.36 | 4.01 | 3.61 |
| Price To Earnings Ratio | 4.4405 | 3.596 | 7.7368 |
| Earnings Growth Rate | -16.2095 | 11.0803 | -32.2702 |
| Price Earnings To Growth Ratio | -0.2739 | 0.3245 | -0.2398 |
| Book Value Per Share | 1.8362 | -0.2743 | 33.2294 |
| Price To Book Ratio | 8.1253 | -52.5792 | 0.8405 |
| Ebitda | 1,822,000,000 | 1,801,000,000 | 1,669,000,000 |
| Enterprise Value | 12,060,126,320 | 11,756,546,380 | 15,311,510,260 |
| Dividend Yield | 0.0774 | 0.0802 | 0.0409 |
| Dividend Payout Ratio | 0.3438 | 0.2884 | 0.3162 |
| Debt To Equity Ratio | 18.8559 | -125.2714 | -10.0011 |
| Capital Expenditures | 130,000,000 | 281,000,000 | 161,000,000 |
| Free Cash Flow | 809,000,000 | 518,000,000 | 697,000,000 |
| Return On Equity | 1.8305 | -14.6143 | -1.028 |
| One Year Beta | 0.7763 | 1.0277 | 0.6567 |
| Three Year Beta | 0.7367 | 0.7295 | 0.6631 |
| Five Year Beta | 0.7357 | 0.7295 | 0.6631 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2025-08-11 | 11,519 | A | 28,899 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2025-08-11 | 4,122 | D | 24,777 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2025-08-11 | 11,519 | D | 11,519 |
| Sequeira Ramona | Director | 2025-07-01 | 21,890 | A | 21,890 |
| COX CARRIE SMITH | Director | 2025-06-13 | 23,904 | A | 74,029 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| John W Hickenlooper | Senator | 2021-07-09 | Sale (Full) | 2021-06-28 | Self | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bill Few Associates, Inc. | 2025-09-30 | 152,920 | 14,318 | 10.6803 |
| 180 WEALTH ADVISORS, LLC | 2025-09-30 | 1,234,298 | 115,571 | 10.68 |
| Darwin Wealth Management, LLC | 2025-09-30 | 10 | 1 | 10 |
| Lowe Wealth Advisors, LLC | 2025-09-30 | 160 | 15 | 10.6667 |
| Capital Advisors, Ltd. LLC | 2025-09-30 | 1,000 | 55 | 18.1818 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| ADVISORS' INNER CIRCLE FUND | 2025-07-31 | Investor Class Shares | LVAVX | 17,000 | 164,900 | 0.1295 |
| ADVISORS' INNER CIRCLE FUND | 2025-07-31 | Institutional Class Shares | LSVVX | 17,000 | 164,900 | 0.1295 |
| E Trade Trust | 2025-07-31 | E*TRADE No Fee Total Market Index Fund | ETTOX | 174 | 1,687.8 | 0.0059 |
| iSHARES TRUST | 2025-07-31 | iShares Morningstar Small-Cap Value ETF | ISCV | 48,462 | 470,081.4 | 0.096 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1000 ETF | PRF | 206,515 | 2,003,195.5 | 0.0257 |